Leukotriene modifiers in pediatric asthma management

Pediatrics

Volumn 107, Issue 2, 2001, Pages 381-390

  Bisgaard, Hans ^a  

^a Mental Health Services CPH   (Denmark)

Author keywords

Asthma; Leukotriene; Leukotriene receptor antagonists; Management; Pediatrics; Positioning; Steroid

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE; NITRIC OXIDE; PEPTIDOLEUKOTRIENE;

ALLERGIC REACTION; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHOSPASM; BRONCHUS OBSTRUCTION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EOSINOPHIL; EXERCISE; HUMAN; HYPERVENTILATION; IN VIVO STUDY; INFLAMMATORY CELL; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; WHEEZING;

ACETATES; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; HUMANS; HYDROXYUREA; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MEMBRANE PROTEINS; QUINOLINES; RECEPTORS, LEUKOTRIENE; TOSYL COMPOUNDS;

EID: 0035145039     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.107.2.381     Document Type: Review

References (121)

1. Characterization of the human cysteinyl leukotriene CysLT1 receptor
2. Enhanced leukotriene C4 production by peripheral eosinophilic granulocytes from children with asthma
3. Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects
4. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma
5. Leukotriene E4 plasma levels in adult asthmatic patients with variable disease severity
6. Persistent increase in plasma and urinary leukotrienes after acute asthma
7. Urinary leukotriene E4 levels during early and late asthmatic responses
8. Urinary excretion of leukotriene E 4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4 and histamine in asthmatics
9. Urinary leukotriene E4 after exercise challenge in children with asthma
10. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist
11. Enhanced arachidonic acid metabolism in alveolar macrophages from wheezy infants. Modulation by dexamethasone
12. The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: Role in obstructive airway disease
13. Release of leukotriene C4 in respiratory tract during acute viral infection
14. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection
15. Increased airway leukotriene levels in infants with severe bronchopulmonary dysplasia
16. Sputum cysteinyl-leukotriene levels correlate with the severity of pulmonary disease in children with cystic fibrosis
17. Bronchial hyperreactivity to leucotriene D4 and histamine in exogenous asthma
18. Bronchial effects of leukotriene D4 inhalation in normal human lung
19. The effect of inhaled leukotriene D4 in humans
20. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma normal controls
21. Leukotrienes C4, D4, and E4 enhance histamine responsiveness in asthmatic airways
22. The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects
23. Maximal airway narrowing to inhaled leukotriene D4 in normal subjects. Comparison and interaction with methacholine
24. The effect of inhaled budesonide on the maximal degree of airway narrowing to leukotriene D4 and methacholine in normal subjects in vivo
25. Leukotriene- and histamine-induced increases in vascular permeability interstitial transport in the skin
26. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans
27. Vascular effects of leukotriene D4 in human skin
28. Cysteinyl leukotrienes enhance growth of human airway epithelial cells
29. Leukotriene D4 facilitates airway smooth muscle cell proliferation via modulation of the 1GF axis
30. Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, contraction in vitro: Differential sensitivity to cysteinyl leukotriene receptor antagonists
31. Role of leukotriene D4 in allergen-induced increases in airway smooth muscle in the rat
32. Leukotrienes, leukotriene receptor antagonists and rhinitis
33. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor
34. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin
35. Effects of leukotrienes C4 and D4 on glycoprotein lysozyme secretion by human bronchial mucosa
36. Slow-reacting substances, leukotrienes C4 and D4 increase the release of mucus from human airways in vitro
37. SRS-A leukotrienes decrease the activity of human respiratory cilia
38. The effects of leukotrienes C4 and D4 on ciliary activity of human paranasal sinus mucosa in vitro
39. Leukotriene E4 granulocytic infiltration into asthmatic airways
40. The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma
41. Comparison of leukotriene B4 and D4 effects on human eosinophil neutrophil motility in vitro
42. Chemotactic activity of LTB4 in man
43. The effect of inhaled leukotriene B4 in normal in asthmatic subjects
44. Effect of a leukotriene B4 receptor antagonist L.Y. 293111, on allergen induced responses in asthma
45. Leukotriene B4 asthma and Thorax
46. Effect of cysteinyl-leukotriene receptor antagonist ICI.219 on allergen-induced bronchoconstriction airway hyperreactivity in atopic subjects
47. Potent leukotriene D4 receptor antagonist ICI.219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction
48. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early late phase airway obstruction in asthmatics
49. Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions
50. Effect of a leukotriene antagonist, ONO-1078 on bronchial hyperresponsiveness in patients with asthma
51. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction airway hyperresponsiveness in asthmatic subjects
52. Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids
53. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma exercise-induced bronchoconstriction
54. The protective effect of inhaled leukotriene D4 receptor antagonist ICI,219 against exercise-induced asthma
55. Inhibition of exercise-induced bronchoconstriction by MK-571 a potent leukotriene D4-receptor antagonist
56. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval
57. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air
58. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects
59. Bronchoprotection from leukotriene receptor antagonist in asthmatic pre-school children
60. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings
61. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial
62. Effect of zafirlukast (Accolate) on airway inflammation after segmental allergen challenge in patients with mild asthma
63. Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial
64. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma
65. Montelukast, a potent leukotriene receptor antagonist, causes dose related improvements in chronic asthma
66. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma
67. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist
68. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma
69. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized double-blind trial
70. Montelukast (MK-0476) improves asthma over a 3 month treatment period in 2- to 5-year-olds
71. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast
72. NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma
73. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078
74. The role of lipocortin in corticosteroid actions
75. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans
76. Urinary leukotriene E4 after antigen challenge and in acute asthma allergic rhinitis
77. Effect of oral prednisone on airway inflammatory mediators in atopic asthma
78. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion
79. Glucocorticosteroids inhibit leukotriene production
80. Zileuton
81. Zileuton for asthma
82. Safety and clinical efficacy of zileuton in patients with chronic asthma
83. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma
84. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial
85. A randomized controlled trial comparing zileuton with theophylline in moderate asthma
86. Zafirlukast. A review of its pharmacology therapeutic potential in the management of asthma
87. Effects of 6 weeks of therapy with oral doses of ICI.,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma
88. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study
89. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction
90. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial
91. The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children
92. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist
93. Montelukast dose selection in 6- to 14-year-olds: Comparison of single-dose pharmacokinetics in children and adults
94. Montelukast added to inhaled beclomethasone in treatment of asthma
95. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
96. Montelukast versus salmeterol in patients with asthma exercise-induced bronchoconstriction
97. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma
98. Montelukast, a leukotriene receptor antagonist, provides additional clinical benefit in asthmatic children aged 6 to 14 years using inhaled corticosteroids
99. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist
100. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids
101. MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human
102. Improved asthma control over 6 weeks with zafirlukast in patients on high dose inhaled corticosteroids
103. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid
104. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene
105. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast
106. Zafirlukast, and Churg-Strauss syndrome
107. Churg-Strauss syndrome associated with zafirlukast
108. Art. Pulmonary eosinophilia associated with montelukast
109. Asthma: A solution to half the puzzle?
110. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription
111. 15-Lipoxygenase immunoreactivity in normal and in asthmatic airways
112. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma
113. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma
114. Long-acting beta2-agonist in management of childhood asthma: A critical review of the literature
115. Inhaled budesonide for treatment of recurrent wheezing in early childhood
116. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: A dose comparison study
117. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma
118. The relationship between airway inflammation and asthma severity
119. Issues in the use of inhaled glucocorticoids